Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

NSE/BALPHARMA stock hub

NSE/BALPHARMA has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/BALPHARMAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.3B

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/BALPHARMA

In the news

Latest news · NSE/BALPHARMA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/E15.9

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC8.5

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/BALPHARMA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

189

Groups with data

Currency

INR

Showing 189 of 189 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	986
Employees Change	118%
Employees Change Percent	13.59
Enterprise value	INR 2.8B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Drug Manufacturers - Specialty & Generic
Isin	INE083D01012
Last refreshed	2026-05-10
Market cap	INR 1.3B
Price	INR 80.28
Price currency	INR
Rev Per Employee	3,138,556.8x
Sector	Healthcare
Sic	2834
Symbol	nse/BALPHARMA
Website	https://www.balpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	6.28%
EV Earnings	33.86x
EV/EBIT	14.47x
EV/EBITDA	10.82x
EV/Sales	0.89x
P/B ratio	1.65x
P/E ratio	15.92x
P/S ratio	0.42x
PE Ratio10 Y	39.23x
PE Ratio3 Y	30.46x
PE Ratio5 Y	30.11x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	6.14%
EBITDA Margin	7.78%
Gross margin	45.42%
Gross Profit	INR 1.4B
Gross Profit Growth	-1.36%
Gross Profit Growth Q	14.41%
Gross Profit Growth3 Y	6.04%
Gross Profit Growth5 Y	11.14%
Net Income	INR 81.2M
Net Income Growth	11.96%
Net Income Growth Q	269.89%
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Net Income Growth3 Y	40.29%
Pretax Margin	1.72%
Profit Margin	2.62%
Profit Per Employee	INR 82,385
Profitable Years	5
Roa5y	4.01
Roe5y	8.94
ROIC	8.48
Roic5y	8.12

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-0.55%
Cagr15y	9.06%
Cagr1y	-15.17%
Cagr3y	0.35%
Cagr5y	-4.26%
Div CAGR10	1.84%
Div CAGR3	6.27%
Div CAGR5	3.71%
EPS Growth	8.49
EPS Growth Q	239.4
EPS Growth Quarters	1
EPS Growth Years	0
EPS Growth3 Y	37.03
Revenue Growth	-2.02x
Revenue Growth Q	19.87x
Revenue Growth Quarters	2x
Revenue Growth Years	0x
Revenue Growth3 Y	1.51x
Revenue Growth5 Y	12.2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	INR 91.3M
Debt	INR 1.5B
Debt EBITDA	INR 6.09
Debt Equity	INR 1.98
Equity	INR 783.3M
Interest Coverage	1.32
Net Cash	INR -1.5B
Net Cash By Market Cap	INR -113
Net Debt EBITDA	INR 6.05
Net Debt Equity	INR 1.86
Tangible Book Value	INR 620.3M
Tangible Book Value Per Share	INR 39.34
WACC	6.94

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-3.2%
Dividend Growth	0%
Dividend Growth Years	0%
Dividend per share	INR 1.2
Dividend Years	5
Dividend Yield	1.58%
Ex Div Date	2025-09-18
Last Dividend	INR 1.2
Payout Frequency	Annual

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-5.36%
1Y total return	-15.16%
200-day SMA	79.11
3Y total return	1.05%
50-day SMA	73.01
50-day SMA vs 200-day SMA	50under200
5Y total return	-19.55%
All Time High	167.9
All Time High Change	-52.19%
All Time High Date	2016-01-13
All Time Low	13
All Time Low Change	517.54%
All Time Low Date	2013-06-21
ATR	3.29
Beta	0.4
Ch YTD	9.49
High	82.5
High52	111.2
High52 Date	2025-06-12
High52ch	-27.79%
Low	78.05
Low52	60
Low52 Date	2026-03-30
Low52ch	33.8%
Ma50ch	9.95%
Price vs 200-day SMA	1.48%
RSI	67.07
RSI Monthly	45.9
RSI Weekly	54.63
Sharpe ratio	-0.66x
Sortino ratio	-0.73
Total Return	-1.62%
Tr YTD	9.49
Tr15y	267.26%
Tr1m	12.06%
Tr1w	6.33%
Tr3m	14.8%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 190.1M
Operating Income Growth	-13.39
Operating Income Growth Q	24.49
Operating Income Growth3 Y	18.45
Operating Income Growth5 Y	198.1
Operating margin	6.14

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	5,462,081%
Shares Insiders	52.16%
Shares Qo Q	0.79%
Shares Yo Y	3.2%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	8,771.45x
Bv Per Share	49.68
Ch10y	-14.87
Ch15y	205.8
Ch1m	12.06
Ch1w	6.33
Ch1y	-16.3
Ch3m	14.8
Ch3y	-2.22
Ch5y	-23.65
Ch6m	-1.93
Change	2.24%
Change From Open	2.86
Close	78.52
Days Gap	-0.6
Depreciation Amortization	50,746,000
Dollar Volume	2,641,533.1
Earnings Date	2026-05-29
EBIT	INR 190.1M
EBITDA	INR 240.8M
EPS	INR 5.06
F Score	2
Fiscal Year End	March
Founded	1,987
Graham Number	74.28438
Graham Upside	-7.47
Income Tax	INR -28.3M
Is Primary Listing	0
Last Earnings Date	2026-02-11
Last Report Date	2025-12-31
Lynch Fair Value	INR 126
Lynch Upside	57.05
Ma150	74.97
Ma150ch	7.08%
Ma20	76.9
Ma20ch	4.4%
Next Earnings Date	2026-05-29
Open	78.05
Payment Date	2025-10-10
Position In Range	50.11
Price Date	2026-05-08
Price EBITDA	INR 5.37
Ptbv Ratio	2.08
Relative Volume	4.1x
Revenue	3,094,617,000x
Tax By Revenue	-0.91x
Tr6m	-1.93%
Volume	32,904

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

NSE/BALPHARMA dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+1.6%

$1.20 annual per share

Payout ratio

n/a

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

+3.7%

0 consecutive years of growth

Total shareholder yield

-1.6%

Next ex-dividend date: 2025-09-18

Performance

NSE/BALPHARMA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/BALPHARMA?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

+52.2%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+3.2%

Negative means the company is buying back shares.

Technical

NSE/BALPHARMA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

67.1

Neutral momentum band

Price vs 200-day MA

+1.5%

50/200-day relationship not available

Beta (5Y)

0.40

Less volatile than the market

Sharpe ratio

-0.66

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/BALPHARMA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/BALPHARMA stock rating?

nse/BALPHARMA is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/BALPHARMA analysis?

The full report lives at /stocks/nse/BALPHARMA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/BALPHARMA?

The latest report frames nse/BALPHARMA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/BALPHARMA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.